Panel · Use case · Medical Affairs

Label Expansion to a New Population.

LiveBenefit-Risk Panel

If we extend the label to this population, does the balance hold, given what we know and do not know about that group?

DecisionWhether the balance holds in a new population

FunctionsRegulatory, medical, safety, real-world evidence

ReaderLifecycle and regulatory leads

Not askedA study design

DepthStandard, four seats

Label Expansion to a New Population is a ready-made use case for Medical Affairs. It ships under the Benefit-Risk Panel template.

For medical affairs leads. You get the effects table, each seat's conclusion, the weighing matrix, the uncertainties and the risk-minimisation measures. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

If we extend the label to this population, does the balance hold, given what we know and do not know about that group?

Who weighs

A new population changes the denominator for every effect. What is known about the group, and what is not, is the main input.

Seat	What it weighs	What it works from
VP Global Regulatory Strategy	Whether the data justify extrapolating the balance to the new group.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.,2International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy.}	FDA benefit-risk guidance and ICH M4E.
Global Medical Affairs Director	How the group differs clinically and what it needs.	Guidelines and clinical evidence.
Head of Pharmacovigilance	Whether risks differ in the group and what is known from routine use.	Safety data.
Global Real-World Evidence Lead	What real-world data add on the new group and how reliable they are.^{3European Medicines Agency. Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence. Final, EMA/99865/2025.}	The EMA reflection paper on real-world data.

What the assessment does

What we do not know is a column. The effects table shows, for each effect, whether the new group was studied. Rows with no data are gaps and not assumed equal to the original population.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.}

Real-world data can fill part of it. The data seat states what the available sources can show about the new group and the burden of showing the data fit for purpose.^{3European Medicines Agency. Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence. Final, EMA/99865/2025.}

Risk minimization for the group. The report lists extra measures, if any, that the new group would need.

Recommended length

Standard

Four functions read the effects differently. Standard depth gives each a seat and shows the weighing matrix and the risk minimization table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the assessment makes

The assessment states what it assumes about the evidence and the setting, and says what each gap limits. Examples for this decision:

Pharmacokinetics in the new group are similar enough to extrapolate.
The safety profile seen in routine use applies to the group.
The group can be identified safely in practice.

Standards, guidance and sources

Frame

FDA, benefit-risk assessment for new drug and biologic products.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products.}
ICH M4E(R2), the CTD efficacy guideline.^{2International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy.}
EMA, reflection paper on real-world data in non-interventional studies, 2025.^{3European Medicines Agency. Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence. Final, EMA/99865/2025.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any effect assumed equal in a group where it was not studied, any group-specific risk with no data, and any reliance on a single real-world source.

What arrives

Decision and therapeutic context
Benefit-risk conclusion
Effects table
What each seat concludes
Weighing matrix by seat and criterion
Uncertainties and sensitivity
Risk minimisation and monitoring
What would change the balance

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists, and the decision stays with you.

It does not design the study that would fill the gaps.

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Read on 9 October 2026.
[2] International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy. The file could not be opened; structure from secondary commentary.
[3] European Medicines Agency. Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence. Final, EMA/99865/2025. Status as given in EMA’s listing; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.